Story perspectives

Novo Nordisk Licenses Parkinson Drug to Cellular Intelligence, Phase-2 Planned

5/12/2026

Summary

Novo Nordisk Licenses STEM-PD

Novo Nordisk licensed its Parkinson’s disease therapy STEM-PD to AI biotech Cellular Intelligence, granting rights.
Cellular Intelligence will lead development, plan a phase 2 study by end-2026 and a trial next year, using AI to speed manufacturing.
The therapy, a stem-cell-derived progenitor in a Phase 1/2 trial with FDA Fast Track status, will generate payments, royalties and equity for Novo Nordisk after it closes its cell-therapy unit in October 2025, cutting 250 jobs.

Summary

Novo Transfers Program

Novo transferred its dormant cell-therapy program to Cellular Intelligence’s STEM-PD platform.
Cellular Intelligence’s capsule-based system aims to generate cell-signaling data at scale to replace trial-and-error steps in regenerative-medicine manufacturing.
The Chan Zuckerberg Initiative invested in Cellular Intelligence’s Series A round, linking the venture to broader AI-driven biology efforts.
The transfer lets Novo cut internal spending and shift downside risk to the startup and its investors.

History

Historical Context

In August 2017 the FDA approved Novartis’ CAR-T therapy Kymriah, the first U.S. gene-edited cell drug, after a Memorial Sloan Kettering trial showed 83% remission in 75 pediatric leukemia patients. Now Novo Nordisk has licensed its stem-cell Parkinson’s candidate STEM-PD to AI-driven Cellular Intelligence, hoping to mimic Kymriah’s rapid path and reshape biotech financing.

1 of 3

Novo Nordisk Licenses STEM-PD

Novo Nordisk licensed its Parkinson’s disease therapy STEM-PD to AI biotech Cellular Intelligence, granting rights.
Cellular Intelligence will lead development, plan a phase 2 study by end-2026 and a trial next year, using AI to speed manufacturing.
The therapy, a stem-cell-derived progenitor in a Phase 1/2 trial with FDA Fast Track status, will generate payments, royalties and equity for Novo Nordisk after it closes its cell-therapy unit in October 2025, cutting 250 jobs.

1 / 3